This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Horizon Pharma: Rayos FDA Approval Thursday Seems Likely

Stocks in this article: HZNP ARNA VVUS AMRN ZLCS

DEERFIELD, Ill. ( TheStreet) -- Horizon Pharma (HZNP - Get Report) should hear good news from U.S. regulators Thursday about its rheumatoid arthritis drug Rayos. Full approval of the drug should be in the bag.

The only conceivable problem I see that could cause FDA to reject Rayos would be an undisclosed manufacturing issue. Absent that, Rayos' clinical data look fine. Rayos is also already approved in Europe where it is sold under the brand name Lodotra.

Perhaps the biggest risk to Horizon going into tomorrow's FDA approval decision is the stock's run from $4 to $7.50 over the past six weeks. That's a big move ahead of a major catalyst and can often lead to a significant sell off once Rayos' approval is announced. We've seen that story play out before, most recently with Vivus (VVUS - Get Report) and Arena Pharmaceuticals (ARNA - Get Report).

Rayos is a delayed-release formulation of low-dose prednisone, a common steroid already well entrenched as a pain reliever used by patients with rheumatoid arthritis. Rayos is taken when a patient goes to bed. The drug's proprietary outer layer dissolves slowly in the gut, releasing the active prednisone after four hours when patients need more pain relief.

Horizon's FDA submission included a study showing Rayos achieves the same blood levels of low-dose prednisone compared to immediate release prednisone, except for the planned four-hour time delay.

Two phase III studies of Rayos were also submitted to FDA for approval review. The first study enrolled 288 rheumatoid arthritis patients, randomized to treatment with either Rayos (taken at bedtime) or immediate-release prednisone (taken in the morning) for 12 weeks. The study demonstrated that Rayos was superior to immediate-release prednisone in reducing the duration of morning stiffness associated with rheumatoid arthritis.

The mean change in morning stiffness of joints from baseline was 23% in Rayos-treated patients compared to 0.4% for patients treated with immediate-release prednisone. The result was statistically significant.

ACR20 response rates (percentage of patients achieving a 20% improvement in swollen joints) were reported to be similar between Rayos and immediate-release prednisone.

The second, phase III study, enrolling 350 rheumatoid arthritis patients, showed a statistically significant improvement in ACR20 response rate favoring Rayos (48.5%) compared to a placebo (28.6%). Rayos' response rates were also superior to placebo when measured by more stringent ACR50 and ACR70 critieria, although only ACR50 was statistically significant.

If approved, Horizons' challenge will be to convince doctors to prescribe Rayos instead of cheap, generic prednisone that costs pennies per pill. Lodotra sales in Europe have been slow although the drug is still in the early phases of its commercial launch.

Zalicus (ZLCS) is also developing a special formulation of prednisone for rheumatoid arthritis pain relief. Results from a mid-stage study are expected this quarter.

Also on Thursday, Amarin (AMRN) is expected to hear from FDA on an approval decision for its prescription fish-oil pill Vascepa.

--Written by Adam Feuerstein in Boston.



>To contact the writer of this article, click here: Adam Feuerstein.

>To follow the writer on Twitter, go to http://twitter.com/adamfeuerstein.

>To submit a news tip, send an email to: tips@thestreet.com.

Follow TheStreet on Twitter and become a fan on Facebook.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,164.95 -251.90 -1.45%
S&P 500 1,994.99 -26.26 -1.30%
NASDAQ 4,635.24 -48.1670 -1.03%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs